CJC-1295 and Ipamorelin
CJC-1295 & Ipamorelin Blend 15MG - Image 2

CJC-1295 & Ipamorelin Blend 15MG

$79.99

CJC-1295 & Ipamorelin Blend

The CJC-1295 and Ipamorelin blend is a powerful combination of peptides designed to synergistically enhance growth hormone (GH) release and promote tissue repair, fat loss, and overall well-being. This blend is widely researched for its potential benefits in anti-aging, athletic performance, and metabolic optimization.

Description

CJC-1295 is a growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary gland to release growth hormone. When paired with Ipamorelin, a growth hormone secretagogue, the blend amplifies natural GH secretion while minimizing undesirable side effects like hunger or cortisol elevation. This combination provides a sustained and steady increase in growth hormone and IGF-1 levels, making it a popular choice for research into regenerative medicine and performance enhancement.

Key Features

  • Enhanced Growth Hormone Release: CJC-1295 provides sustained GH release, while Ipamorelin offers rapid, pulsatile stimulation, creating a complementary effect.
  • Muscle Growth and Repair: Promotes protein synthesis and muscle recovery, aiding in hypertrophy and tissue regeneration.
  • Fat Loss: Supports lipolysis and metabolic efficiency, helping reduce body fat while preserving lean muscle mass.
  • Anti-Aging Benefits: Improves skin elasticity, boosts energy levels, and supports overall cellular repair processes.
  • Improved Sleep Quality: Enhances deep sleep (slow-wave sleep), which is critical for recovery and hormone regulation.

Research Focus

  • Tissue Regeneration: Investigating its applications in muscle repair, wound healing, and recovery from injuries.
  • Metabolic Health: Exploring its potential in reducing visceral fat, improving insulin sensitivity, and supporting weight loss.
  • Anti-Aging Studies: Evaluating its effects on age-related decline in GH and IGF-1 levels.
  • Performance Optimization: Researching its role in enhancing strength, endurance, and recovery in athletes (for research purposes only).

Safety and Usage

This compound is intended solely for research purposes and is not approved for human consumption. Researchers must handle it in controlled laboratory environments and follow proper safety protocols. Potential side effects may include mild water retention, temporary injection site irritation, or, in rare cases, hormonal imbalances. Proper dosing and adherence to research guidelines are crucial to minimize risks.

Trusted Seal
Category:

Description

CJC-1295 & Ipamorelin Peptide Blend

The CJC-1295 & Ipamorelin blend combines two distinct growth hormone secretagogues—CJC-1295, a synthetic GHRH (growth hormone-releasing hormone) analog, and Ipamorelin, a selective ghrelin receptor agonist. This dual-peptide formulation is designed to synergistically stimulate endogenous growth hormone (GH) secretion by acting on separate but complementary pathways in the hypothalamic-pituitary axis.

CJC-1295 operates by mimicking the natural GHRH, binding to GHRH receptors in the pituitary and promoting pulsatile GH release. When modified with Drug Affinity Complex (DAC), its half-life is significantly extended, allowing for prolonged activity. Ipamorelin, on the other hand, stimulates GH secretion by mimicking ghrelin at the growth hormone secretagogue receptor (GHS-R1a) with minimal impact on cortisol or prolactin levels, distinguishing it from earlier secretagogues.

Chemical Makeup

  • CJC-1295 (with DAC):

    • Molecular Formula: C165H269N47O46

    • Molecular Weight: ~3647.10 g/mol

    • Half-Life: ~5–8 days with DAC

  • Ipamorelin:

    • Molecular Formula: C49H74N14O10

    • Molecular Weight: ~711.9 g/mol

    • Half-Life: ~2 hours

  • Form: Lyophilized powder blend

  • Solubility: Water-soluble (reconstitution with bacteriostatic water)

Research & Preclinical Investigations

Synergistic GH Secretion

Combining CJC-1295 and Ipamorelin may produce a more robust and sustained GH release than either compound alone. CJC-1295 enhances baseline GH levels and maintains a pulsatile release, while Ipamorelin provides an acute spike without disrupting the feedback loops of ACTH or cortisol, as observed in animal studies.

IGF-1 Upregulation

Both peptides have been shown to elevate insulin-like growth factor-1 (IGF-1) levels in experimental models. IGF-1 is a downstream mediator of GH, contributing to tissue growth, muscle hypertrophy, bone density, and cellular repair. The co-administration of these peptides in research settings has demonstrated enhanced IGF-1 synthesis and retention over time.

Muscle, Bone, and Recovery Research

Rodent and in vitro models have demonstrated that CJC-1295 and Ipamorelin may enhance satellite cell activation, muscle protein synthesis, and osteoblast activity, making this combination a focus in musculoskeletal recovery, wound healing, and regenerative studies. The blend has also been studied for its influence on sleep quality, metabolic rate, and fat oxidation via GH-mediated pathways.

Research Use Only

The CJC-1295 & Ipamorelin blend is intended solely for in vitro and in vivo laboratory research. It is not approved for human consumption, clinical applications, or diagnostic use. Handle and store under institutional safety protocols.

References

  1. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of GH and IGF-1 secretion by CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab. 2006;91(2):799–805.

  2. Feighner SD, et al. Ipamorelin: a selective GH secretagogue. Endocrinology. 1998;139(10):4080–4088.

  3. Liu L, et al. GH-releasing peptides and their biological effects in rats. Peptides. 2000;21(5):751–755.

  4. Walker RF, et al. Growth hormone secretagogues: Chemistry, biology, and clinical applications. Curr Drug Targets Immune Endocr Metabol Disord. 2004;4(3):235–253.

Additional information

Bundle

Buy 1, Buy 2, Buy 3, Buy 4, Buy 5

Related products